Behind every injectable medicine stands an object so ordinary it is forgotten: the glass that contains it. Yet across an entire market, not a single ampoule or vial of pharmaceutical borosilicate glass is produced — close to a billion units a year, every one of them imported. CRYSTALIUM INDUSTRY exists to end that dependency at its source.

This is a first where there was none. CRYSTALIUM INDUSTRY is built to become the producer of medical-grade borosilicate ampoules and vials where the entire need has, until now, crossed a border to be met. The site stands ready, the authorizations are granted, the equipment supplier is appointed and the lines are already ordered — this is not an intention, it is an industry taking shape.

The process begins with borosilicate glass tubing, drawn into precise ampoules and vials through high-temperature forming and sealing — the exacting craft of converting raw tube into primary packaging that medicine can trust. The build is deliberate, in two phases. The first covers the essential national need in ampoules — 2 ml, 5 ml and 10 ml — at four hundred million units a year. By the third year, capacity rises toward one billion units, extending into glass vials and the formats the market still imports today. Step by step, what was bought abroad becomes made at home.

Every unit answers the most demanding pharmaceutical standards: the thermal resistance and chemical neutrality of true borosilicate, engineered to eliminate any leaching and to preserve the stability and purity of the medicines it will hold.

And there is a deeper logic at work. CRYSTALIUM closes the most upstream link of the entire chain: the corticosteroid is made within the group, the capsule is made within the group — and now the very glass that carries the injectable is formed within it too. Nothing essential is left outside. From the glass tube to the sealed container, the foundation of medicine is built, not bought.

A medicine that cannot reach the patient is a medicine that does not exist. AZELIUM LOGISTICS exists so that nothing the group produces ever depends on someone else to complete its journey — from the production line to the pharmacy shelf, from the factory to the far side of a border.

This is integration carried to its conclusion. Where most manufacturers hand their products to outside distributors and lose control at the warehouse door, AZELIUM LOGISTICS keeps the entire chain within the group: a commercial arm that places AZELIUM products across the market, a dedicated pharmaceutical transport division that carries them under strict temperature-controlled, cold-chain conditions, and an international branch built to export what the group is uniquely positioned to ship — beginning with capsules and corticosteroids.

Each function answers the same standard. Compliant with international Good Distribution Practices, every shipment moves under controlled climate parameters, fully traceable, secure from origin to destination. But the deeper advantage is structural: because LOGISTICS belongs to the group it serves, there is no broken link, no handoff, no loss of control between the molecule and the market.

This is what closes the circle. AZELIUM produces, AZELIUM transports, AZELIUM delivers — and AZELIUM exports. From the sterile line to the patient’s hand, and from the home market to the world, the chain is never surrendered.

Because in pharmaceuticals, whoever controls the flow controls the future of the medicine itself.

A pharmaceutical industry is not measured only by its most complex product, but by its capacity to turn a single mastery into many. AZELIUM GENERICS is exactly that: the extension of a hard-won expertise — born in sterile corticosteroid manufacturing — into the wide field of everyday medicine.

The logic is one of continuity, not improvisation. The same industrial discipline, the same quality standards, and the same equipment partner that built our corticosteroid lines now serve a broad generic portfolio across the therapies daily life depends on — anti-infectives, antipyretics, gastrointestinal treatments and well beyond — in solid forms, oral forms and topical ointments. What is demanding to learn once becomes natural to repeat, and that is where true industrial depth begins.

The groundwork is already laid. The site stands ready, the equipment comes from a partner we already know, and the product dossiers are prepared. On this foundation, AZELIUM GENERICS is built to reach a portfolio of around one hundred products within three to five years — not a distant ambition, but the methodical unfolding of a capability that already exists.

This is the quiet strength of an integrated group: every mastery feeds the next. The science that fills a sterile vial also shapes a tablet, a coated capsule, a tube of ointment — the same rigor, carried into every home and every hospital. From the most critical therapy to the most common remedy, the standard never changes.

Because true health security is not built on a single medicine. It is built on the ability to make them all.

The most advanced medicines of our time are biological. They are also the most distant — produced in a handful of laboratories, reaching the rest of the world late, dependent, and at a price set elsewhere. AZELIUM BIO-TECH was created to close that distance.

We begin where it matters: with what already stands. A dedicated, high-grade sterile facility. International-class cleanrooms. And an active operation in the secondary conditioning of biotechnological products — handling, today, the most sensitive therapies under the most demanding conditions. This is not a plan on paper. It is a working platform, built to the standards the world’s most regulated medicines require.

On this foundation, we are building the next step. A dedicated team maintains constant technological watch over the biotech frontier, while we advance partnerships with leading international groups to manufacture, on home ground, the biological therapies our market now demands — including the advanced treatments that the gravest illnesses depend on.

The method is deliberate: master the handling before the making, the cleanroom before the bioreactor, the standard before the scale. Biotechnology forgives no shortcut, and we take none. Every capability we acquire is acquired completely, through full technology transfer, so that what we produce tomorrow rests on mastery, not dependence.

From the most controlled environments to the most complex molecules, AZELIUM BIO-TECH advances toward a single conviction: that the frontier of medicine should never be a foreign country — and that hope, like everything we build, can be made at home.

Every oral medicine begins with a shell. For decades that shell was bought elsewhere — a quiet dependency hidden inside every capsule on every shelf. AZELIUM CAPS exists to end it: to produce, where they were once only imported, the empty hard capsules on which an entire pharmaceutical industry rests.

This is heavy capacity, built to industrial scale. Three production modules, eight lines each, raised within a sterile industrial environment, engineered toward a capacity of twenty billion capsules a year. Across the full range of sizes and both chemistries that the market demands — animal-gelatin and plant-based HPMC — AZELIUM CAPS masters what few producers control end to end, through integral technology transfer for each.

The ambition is matched by a method. From the first year of operation, AZELIUM CAPS is built to cover its home market in full — every size, every standard, no gap left to imports. Within two years, that same capacity turns outward, toward international markets that still depend on what we will already produce at scale.

Engineered for flawless performance on the highest-speed filling lines, every capsule protects its active ingredient and delivers the uniform dissolution modern medicine requires. But the true value runs deeper: to control the shell is to secure the chain. Whoever masters what holds the medicine holds the foundation of the medicine itself.

From the raw material to the finished shell, nothing is approximate, and nothing is left to others. The smallest component, mastered completely — because independence is built one capsule at a time.

AZELIUM PHARM is built around a mastery few possess: the end-to-end production of injectable corticosteroids through lyophilization — the science of sublimating a liquid into a pure, stable powder, rather than merely filling powder that others have made.

This is not fill-and-finish. It is one of the most demanding processes in sterile pharmaceutical manufacturing. To grasp how rare it is: in a nation the size of China, only seven holders command this corticosteroid lyophilization technology. AZELIUM PHARM brings that mastery to the ground floor of an entire market — from the raw active ingredient to the sealed sterile vial, under a single roof and a single standard.

Across five essential molecules — methylprednisolone, hydrocortisone, betamethasone, dexamethasone and triamcinolone — AZELIUM PHARM produces the anti-inflammatory and immunosuppressive therapies that intensive care, surgery and specialized medicine cannot do without.

And because a medicine is only as useful as its reach, our production serves two channels at once: a public-officine range, available to pharmacies and patients, and a specialized hospital range developed for central hospital supply. Everyday care and critical care, mastered on the same lines.

From the liquid to the crystal, from the molecule to the vial — nothing here is imported, nothing is approximate. Where life is at stake, dependence has no place.